Article info
PDFClinical and epidemiological research
Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis
- Sudha Visvanathan, Centocor Research and Development, Inc., 200 Great Valley Parkway, Mailstop RA-1-4; Malvern, PA 19355, USA; svisvana{at}cntus.jnj.com
Citation
Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis
Publication history
- Accepted March 16, 2008
- First published May 21, 2008.
Online issue publication
November 02, 2019
Article Versions
- Previous version (2 November 2019).
- You are viewing the most recent version of this article.
web only appendices 68/2/175
Files in this Data Supplement:
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Visvanathan et al 2009 This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.